117011-70-8

Basic information

• Product Name: 2-(4-Aminophenoxy)-2-methylpropionic acid
• Synonyms: 2-(4-AMINOPHENOXY)-2-METHYLPROPANOIC ACID;2-(4-AMINO-PHENOXY)-2-METHYL-PROPIONIC ACID;Propanoic acid, 2-(4-aMinophenoxy)-2-Methyl-;2-(4-Aminophenoxy)-2-methyl-propanoic acid HCl
• CAS NO: 117011-70-8
• Molecular Formula: C₁₀H₁₃NO₃
• Molecular Weight: 195.22
• Product Categories: pharmacetical
• Mol File: 117011-70-8.mol

Chemical Properties

• Melting Point: 214-216 °C (decomp)
• Boiling Point: 364.6 °C at 760 mmHg
• Flash Point: 174.3 °C
• Appearance: /
• Density: 1.22 g/cm³
• Vapor Pressure: 5.9E-06mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.08±0.10(Predicted)
• CAS DataBase Reference: 2-(4-Aminophenoxy)-2-methylpropionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Aminophenoxy)-2-methylpropionic acid(117011-70-8)
• EPA Substance Registry System: 2-(4-Aminophenoxy)-2-methylpropionic acid(117011-70-8)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 117011-70-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-Aminophenoxy)-2-methylpropionic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with unique therapeutic properties.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 2-(4-Aminophenoxy)-2-methylpropionic acid serves as a building block for the creation of a wide range of organic compounds, leveraging its structural and reactive features to enhance the properties of the final products.
Used in Medicine:
2-(4-Aminophenoxy)-2-methylpropionic acid is utilized in the medical field for its potential applications in drug development, offering a foundation for the design of innovative therapeutic agents that address unmet medical needs.
Used in Biotechnology:
2-(4-Aminophenoxy)-2-methylpropionic acid finds applications in biotechnology, where its reactivity and structural attributes can be harnessed for the engineering of novel bioactive molecules with specific biological functions.
Used in Materials Science:
2-(4-Aminophenoxy)-2-methylpropionic acid also holds promise in materials science, where it can be incorporated into the development of advanced materials with tailored properties for various applications.

InChI:InChI=1/C10H13NO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,11H2,1-2H3,(H,12,13)

Upstream product

• 103-90-2 4-acetaminophenol 
• 2052-01-9 2-bromo-2-methylpropionic acid 
• 123-30-8 4-amino-phenol 
• 100-02-7 4-nitro-phenol 
• 79925-16-9 2-(4-cyanophenoxy)-2-methylpropionic acid 
• 767-00-0 4-cyanophenol 
• 7159-95-7 (4-hydroxyphenyl)carbamic acid ethyl ester 
• 121809-55-0 2-<4-<(ethoxycarbonyl)amino>phenoxy>-2-methylpropionic acid 
• 121809-54-9 2-(4-carbamoylphenoxy)-2-methylpropionic acid 
• 17413-84-2 2-(4-acetaminophenoxy)-2-methylpropionic acid 
• 17431-97-9 2-(4-nitrophenoxy)-2-methylpropanoic acid 

Downstream Products

• 17413-84-2 2-(4-acetaminophenoxy)-2-methylpropionic acid 
• 121809-79-8 2-{4-[3-(2,5-Dichloro-phenyl)-ureido]-phenoxy}-2-methyl-propionic acid 
• 1338359-09-3 2-(4-benzylamino-phenoxy)isobutyric acid 
• 121809-83-4 2-Methyl-2-{4-[3-(3-nitro-phenyl)-ureido]-phenoxy}-propionic acid 
• 121809-74-3 2-{4-[3-(2-Chloro-phenyl)-ureido]-phenoxy}-2-methyl-propionic acid 
• 121809-76-5 2-{4-[3-(4-Chloro-phenyl)-ureido]-phenoxy}-2-methyl-propionic acid 
• 121809-59-4 2-<4-<<<(4-chlorophenyl)amino>imino>methyl>phenoxy>-2-methylpropionic acid 
• 121809-85-6 4-(4-chloro-3-nitrophenylureido)phenoxyisobutyric acid 
• 121809-90-3 4-(4-ethylcarbamatophenylureido)phenoxyisobutyric acid 
• 121809-69-6 4-(3,4-dimethoxyphenylureido)phenoxyisobutyric acid 
• 121809-94-7 4-(4-carboxyphenylureido)phenoxyisobutyric acid 
• 121809-78-7 2-{4-[3-(2,4-Dichloro-phenyl)-ureido]-phenoxy}-2-methyl-propionic acid 
• 121809-67-4 4-(2,4,6-trimethylphenylureido)phenoxyisobutyric acid 
• 121809-91-4 2-(4-(3,5-dichlorobenzamido)phenoxy)-2-methylpropionic acid 

Relevant articles and documents

Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents

A novel series of substituted quinazoline derivatives were designed, synthesized and evaluated for their hypolipidemic activity in cholesterol induced hyperlipidemic rats. In vivo screening concluded that compounds A-4, C-5 and C-6 have shown potent antihyperlipidemic activity by decreasing the plasma level of triglycerides (TG), very low density lipoprotein (VLDL), low density lipoprotein (LDL), followed by increase in level of high density lipoprotein (HDL).

Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors

A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in radiation oncology applications. The compounds are capable of acting on hemoglobin in whole blood.

Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood

A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Allosteric modifiers of hemoglobin

A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Medical uses of allosteric hemoglobin modifier compounds in patient care

A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgical blood loss, acute nonvolemic hemodilutions, wounds, diabetic ulcers, chronic leg ulcers, pressure sores, tissue transplants, and sepsis. The compounds are capable of acting on hemoglobin in whole blood.

Allosteric hemoglobin modifiers to decrease oxygen affinity in blood

A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood dur

Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood

A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood dur

Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood

Compounds of the general structural formula: STR1 wherein X, Y and Z may each be CH2, NH, or O, R2-6 are either hydrogen, halogen, or a substituted or unsubstituted C1, C2, or C3 alkyl group and these

Allosteric Modifiers of Hemoglobin. 1. Design, Synthesis, Testing, and Structure-Allosteric Activity Relationship of Novel Hemoglobin Oxygen Affinity Decreasing Agents

Three isomeric series of 2-(aryloxy)-2-methylpropionic acids were prepared and studied for their ability to decrease the oxygen affinity of human hemoglobin A.The isomeric aryloxy groups included 4-methyl>phenoxy, 4-(arylacetamido)phenoxy, and 4-methyl>phenoxy.A total of 20 compounds were synthesized and tested.Structure-activity relationships are presented.Several of the new compounds were found to be strong allosteric effectors of hemoglobin.The two most active compounds are 2-methyl>phenoxy>-2-methylpropionic acid and the corresponding 3,5-dimethyl derivative.The latter two compounds have been compared to other known potent allosteric effectors in the same assay and show greater activity.Both compounds also exhibit a right shift in the oxygen equilibrium curve when incubated with whole blood.The new compounds may be of interest in clinical or biological areas that require or would benefit from a reversal of depleted oxygen supply (i.e., ischemia, stroke, tumor radiotherapy, blood storage, blood substitutes, etc.).They are also structurally related to several marketed antilipidemic agents.

Allosteric hemoglobin modifiers

Allosteric hemoglobin modifier compounds having the general formula STR1 wherein X and Z may be CH2, NH or O.